1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1851 ◽

2021 ◽

Vol 32 ◽

pp. S981

Author(s):

T. Hida ◽

M. Nishino ◽

K. Yoh ◽

T. Asato ◽

T. Kitagawa ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Dose Escalation Study ◽

Download Full-text

PD3-1-1: ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283395.45098.ca ◽

2007 ◽

Vol 2 (8) ◽

pp. S458-S459

Author(s):

Ross Soo ◽

Choon-Hua Thng ◽

Norita Sukri ◽

Chiung-Ing Wong ◽

Soo-Chin Lee ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Phase I ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Dose Escalation Study

Download Full-text

Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2540 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2540-2540 ◽

Author(s):

D. S. Hong ◽

B. S. Koetz ◽

R. Kurzrock ◽

N. N. Senzer ◽

W. Hanekom ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Dose Escalation Study

Download Full-text

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

10.18632/oncotarget.18554 ◽

2017 ◽

Vol 8 (45) ◽

pp. 79546-79555 ◽

Author(s):

Kohei Shitara ◽

Tae Min Kim ◽

Tomoya Yokota ◽

Masahiro Goto ◽

Taroh Satoh ◽

...

Keyword(s):

Gastric Cancer ◽

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Download Full-text

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-14-0409 ◽

2014 ◽

Vol 20 (24) ◽

pp. 6284-6294 ◽

Author(s):

L. Rhoda Molife ◽

Emma Jane Dean ◽

Montserrat Blanco-Codesido ◽

Matthew G. Krebs ◽

Andre T. Brunetto ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Dose Escalation ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-2019-3 ◽

2012 ◽

Vol 71 (2) ◽

pp. 463-471 ◽

Author(s):

Raoul Tibes ◽

Gil Fine ◽

Gavin Choy ◽

Sanjeev Redkar ◽

Pietro Taverna ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Download Full-text

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2531-2531 ◽

Author(s):

T. Evans ◽

C. R. Lindsay ◽

E. Chan ◽

B. Tait ◽

S. A. Michael ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Insulin Receptor ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study

Download Full-text

Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor

Annals of Oncology ◽

10.1093/annonc/mdx380.080 ◽

2017 ◽

Vol 28 ◽

pp. v493 ◽

Author(s):

K. Park ◽

F. Ciardiello ◽

T. Hida ◽

W. Lim ◽

C-C. Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

European Journal of Cancer ◽

10.1016/j.ejca.2014.11.003 ◽

2015 ◽

Vol 51 (2) ◽

pp. 137-145 ◽

Author(s):

J. Spicer ◽

R. Baird ◽

A. Suder ◽

N. Cresti ◽

J. Garcia Corbacho ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Phase 1 ◽

Solid Tumours ◽

Dose Escalation Study

Download Full-text

A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.14521 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 14521-14521

Author(s):

S. R. Malireddy ◽

E. G. Chiorean ◽

A. Younger ◽

D. Jones ◽

M. Waddell ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Vegfr Tyrosine Kinase Inhibitor

Download Full-text

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

European Journal of Cancer ◽

10.1016/j.ejca.2009.05.010 ◽

2009 ◽

Vol 45 (13) ◽

pp. 2333-2341 ◽

Author(s):

J.C. Soria ◽

C. Massard ◽

N. Magné ◽

Th. Bader ◽

C.D. Mansfield ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Phase 1 ◽

Dose Escalation Study

Download Full-text